Hinge Health, Inc. Form 4 Filings

Hinge Health, Inc. disclosed that investment funds affiliated with Bessemer Venture Partners sold Class A Common Stock in open-market transactions. On May 7, 2026, Bessemer Venture Partners X L.P. sold 154,740 shares and Bessemer Venture Partners X Institutional L.P. sold 145,260 shares at a weighted average price of $54.77 per share, in multiple trades between $54.10 and $55.00. On May 8, 2026, the same funds sold 103,160 and 96,840 shares, respectively, at a weighted average price of $55.16, with trade prices ranging from $55.04 to $56.02. Reporting person Robinson Elliott, a partner at Bessemer Venture Partners, has an indirect, passive economic interest in these holdings and disclaims beneficial ownership except to the extent of any pecuniary interest.

Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported converting and selling shares of the company’s stock. On May 6, 2026, he converted 50,000 shares of Class B Common Stock into Class A Common Stock and then sold 50,000 Class A shares in open-market transactions at a weighted average price of $55.0087 per share, with individual prices ranging from $55.00 to $55.05. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, he reported no directly held Class A shares, while continuing to hold Class B shares indirectly through a family trust and a Grantor Retained Annuity Trust that are convertible into Class A stock.

Hinge Health, Inc. director and CEO & Co-Founder Daniel Antonio Perez reported insider transactions involving Class A and Class B Common Stock. Through an account noted as held "By Spouse," he sold 150,000 shares of Class A Common Stock on May 6 and May 7, 2026 in open-market transactions at weighted average prices of $55.0884 and $55.0503 per share, respectively, under a Rule 10b5-1 trading plan adopted with his spouse on September 11, 2025.

The sales were paired with conversions of an equivalent number of Class B Common Stock into Class A Common Stock. After these indirect transactions, his spouse’s account held 35,470 Class A shares and 358,445 Class B shares. Separately, Perez directly held Class B Common Stock that was convertible into 9,488,845 Class A shares, showing he retains a substantial equity position despite the pre-planned sales.

Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 831 shares of Class A Common Stock were relinquished and cancelled at an indicated price of $44.60 per share to cover federal and state tax withholding obligations.

The footnote explains this exempt transaction under Section 16b-3(e) was a payment of tax liability by delivering or withholding securities, not an open-market sale. Following the withholding and cancellation, Pursley directly holds 730,442 shares of Class A Common Stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported a routine share disposition tied to tax withholding obligations. On May 1, 2026, 4,614 shares of Class A Common Stock were relinquished and cancelled at an indicated value of $44.60 per share to cover federal and state taxes from vesting restricted stock units.

The footnote explains this exempt transaction was processed under Section 16b-3(e), with the issuer agreeing to satisfy the tax liability in exchange for the cancelled shares. Following this tax-withholding disposition, Budge held 392,199 shares of Hinge Health stock directly. This event reflects compensation-related tax settlement rather than an open-market sale.

Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported an insider transaction involving a conversion and sale of shares. He converted 33,333 shares of Class B Common Stock into Class A Common Stock and then sold 33,333 Class A shares in an open-market transaction at a weighted average price of $45.0463 per share, with prices ranging from $45.00 to $45.44, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, he reported direct ownership of 1,759,769 shares of Class B Common Stock and indirect Class B holdings convertible into 383,592 Class A shares through a family trust and 1,092,119 Class A shares through a GRAT, plus an additional 944,250 performance stock units that are excluded from the reported amounts.

Hinge Health, Inc. director Tyler Sloat acquired 68 shares of Class A Common Stock through the settlement of fully vested restricted stock units on April 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program. Following this equity grant, Sloat directly holds 9,964 Class A shares.

Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg converted 50,000 shares of Class B Common Stock into 50,000 shares of Class A Common Stock and then sold all of those Class A shares in open-market transactions.

The sales covered 49,332 shares at a weighted average of $38.448 and 668 shares at a weighted average of $39.0167, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. Following these trades, he held no Class A shares directly but continued to hold 1,793,102 Class B shares directly, plus additional Class B shares through a GRAT and a family trust that are convertible into over 1.47 million Class A shares. The filing also notes 944,250 performance stock units held by Mecklenburg, which are excluded from the share totals.

Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition. On this Form 4, 831 shares of Class A Common Stock were withheld and cancelled at a value of $38.56 per share to cover federal and state tax withholding from the vesting of restricted stock units. After this transaction, Pursley directly holds 731,273 shares of Hinge Health Class A Common Stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported a disposition of 4,614 shares of Class A Common Stock on a tax-withholding basis. The shares were relinquished to the company at $38.56 per share to cover federal and state tax obligations from vesting restricted stock units. Following this exempt transaction under Section 16b-3(e), Budge directly holds 396,813 shares of Class A Common Stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported selling a total of 11,006 shares of Class A Common Stock on March 23, 2026 in three open-market transactions. The reported weighted average sale prices were $41.2858, $42.4514 and $42.8023 per share, each with specified intraday price ranges.

These sales were effected under a Rule 10b5-1 trading plan adopted by Budge on June 12, 2025, indicating they were pre-arranged. Following the transactions, he directly owns 401,427 shares of Hinge Health Class A Common Stock.

Hinge Health, Inc. president James Pursley sold 15,000 shares of Class A Common Stock in open-market transactions. The sales on March 23, 2026 were split into three trades: 2,256 shares at $41.2126, 9,838 shares at $42.3571, and 2,906 shares at $42.7538.

These trades were executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. After the transactions, Pursley directly owned 732,104 shares of Hinge Health Class A Common Stock.

Sloat Tyler reported acquisition or exercise transactions in this Form 4 filing.

Hinge Health, Inc. director Tyler Sloat received an award of 9,896 shares of Class A Common Stock as a grant, reported at a price of $0.00 per share. After this transaction, he directly holds 9,896 shares.

The filing explains that these 9,896 shares are restricted stock units (RSUs), which vest in accordance with the terms of the award. Each RSU represents a contingent right to receive one share of Class A Common Stock, so the actual share delivery depends on future vesting conditions.

Hinge Health, Inc. Executive Chairman and Co‑Founder Gabriel M.I. Mecklenburg converted 166,666 shares of Class B Common Stock into an equal number of Class A shares on March 6, 2026 at a conversion price of $0.0000 per share. He then sold all 166,666 Class A shares in open‑market transactions at weighted average prices of $45.0224 and $45.6031, as part of a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. Following these transactions, he directly holds 1,843,102 shares of Class B Common Stock and has additional indirect Class B holdings through a GRAT and a family trust that are convertible into 1,092,119 and 383,592 shares of Class A Common Stock, respectively. The filing also notes 944,250 performance stock units held by Mecklenburg are excluded from these share counts.

Hinge Health, Inc. President James Pursley reported a tax-related share disposition. On March 1, 2026, he relinquished 5,127 shares of Class A Common Stock at a value of $42.76 per share. These shares were cancelled by the company to satisfy his federal and state tax withholding obligations from the vesting of restricted stock units. After this exempt tax-withholding transaction, Pursley directly owned 747,104 shares of Hinge Health Class A Common Stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported a tax-related share disposition. On March 1, 2026, he relinquished 7,699 shares of Class A common stock at $42.76 per share, which were cancelled to cover federal and state tax withholding from vesting restricted stock units. After this exempt tax-withholding transaction, he beneficially owned 412,433 shares of Class A common stock.

Hinge Health, Inc. president James Pursley reported selling a total of 15,000 shares of Class A Common Stock in open-market transactions on February 23, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025.

The shares were sold in three tranches at weighted average prices of $38.76, $39.95, and $40.46, with disclosed price ranges for each group of trades. After these sales, Pursley directly owned 752,231 shares of Hinge Health Class A Common Stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 14,763 shares of Class A common stock on February 23, 2026, at weighted average prices between roughly $38.40 and $40.46 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. After these transactions, Budge directly owned 420,132 shares of Hinge Health Class A common stock.

Hinge Health, Inc. director and 10% owner Robinson Elliott filed a Form 4 reporting open-market sales of Class A Common Stock by affiliated Bessemer funds. On February 17, 2026, Bessemer Venture Partners X L.P. sold 46,276 shares and Bessemer Venture Partners X Institutional L.P. sold 43,440 shares at a weighted average price of $39.929. On February 18, 2026, BVP X sold 48,353 shares and BVP X Inst sold 45,390 shares at a weighted average price of $40.358. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these holdings and disclaims beneficial ownership beyond any pecuniary interest.

Hinge Health, Inc. director, CEO and co-founder Daniel Antonio Perez reported indirect changes in ownership of Class A and Class B common stock held by his spouse. On February 17, 2026, 7,260 shares of Class B Common Stock were converted into 7,260 shares of Class A Common Stock at a price of $0.00 per share. The same day, 7,260 shares of Class A Common Stock held indirectly through his spouse were transferred as a bona fide gift, also at $0.00 per share. Following these transactions, spouse-held Class A Common Stock stood at 35,470 shares and spouse-held Class B Common Stock at 508,445 shares, while 9,488,845 shares of Class B Common Stock were reported as directly held.

Hinge Health director and 10% owner Robinson Elliott, through Bessemer venture funds, reported indirect sales of the company’s Class A common stock. On February 12, 2026, Bessemer Venture Partners X L.P. sold 12,086 shares and Bessemer Venture Partners X Institutional L.P. sold 11,346 shares at a weighted average price of $40.096, in multiple trades between $40.025 and $40.115. On February 13, 2026, BVP X sold 77,328 shares and BVP X Inst sold 72,591 shares at a weighted average price of $40.109, with prices ranging from $39.50 to $40.722. Elliott has an indirect, passive economic interest in these Bessemer funds and disclaims beneficial ownership of their securities except to the extent of his pecuniary interest.

Hinge Health, Inc. CEO, Co-Founder, director and 10% owner Daniel Antonio Perez reported a planned share sale. On February 12, 2026, he converted 166,665 shares of Class B Common Stock into the same number of Class A shares at $0 per share, then sold 166,665 Class A shares in open-market transactions at a weighted average price of $40.2635, under a Rule 10b5-1 trading plan adopted on September 11, 2025. Following these transactions, his directly held Class A position reported in this filing is 0 shares, while he directly holds 9,488,845 Class B shares and has additional indirect holdings through his spouse.

Hinge Health, Inc. president James Pursley reported an exempt tax-withholding transaction involving company stock. On 02/01/2026, 1,429 shares of Class A Common Stock were withheld at $34.90 per share to cover federal and state tax obligations from vesting restricted stock units.

These shares were relinquished by Pursley and cancelled by Hinge Health in exchange for the company paying his related tax liabilities. After this administrative transaction, he beneficially owned 767,231 shares of Class A Common Stock directly.

Hinge Health, Inc. Chief Financial Officer James Budge reported an exempt share withholding tied to equity compensation. On 02/01/2026, 3,036 shares of Class A common stock were disposed of at $34.9 per share to cover tax obligations from vested restricted stock units under Section 16b-3(e).

All 3,036 shares were relinquished by the officer and cancelled by the company in exchange for the company paying his federal and state tax withholding liabilities. After this transaction, he beneficially owned 434,895 Class A common shares in direct form.

Hinge Health, Inc. CEO, Co-Founder, director and 10% owner reported insider transactions dated 01/05/2026. The reporting person converted 166,665 shares of Class B Common Stock into 166,665 shares of Class A Common Stock at an exercise price of $0, then sold 122,368 Class A shares at a weighted average price of $46.2458 and a further 44,297 Class A shares at a weighted average price of $46.7664.

The sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025. Following these transactions, indirect holdings include 35,470 Class A shares held by a spouse, and derivative holdings include 14,376,762 shares of Class B Common Stock and 515,705 Class A shares through a spouse, each Class B share being convertible into one Class A share as described in the company’s charter.

Hinge Health, Inc. reported an insider equity transaction by its President on a Form 4. On 01/01/2026, the officer disposed of 1,118 shares of Class A common stock at $46.45 per share under transaction code F, which indicates shares withheld to cover taxes on vesting equity awards. After this tax-related share withholding, the reporting person beneficially owned 768,660 shares of Class A common stock, held directly. The filing notes that the shares relinquished were cancelled by the company in exchange for the company’s agreement to satisfy the officer’s federal and state tax withholding obligations arising from the vesting of restricted stock units.

Hinge Health, Inc. reported that its Chief Financial Officer disposed of Class A common stock in a routine tax-related transaction. On 01/01/2026, the CFO had 3,243 shares of Class A common stock withheld and cancelled at a value of $46.45 per share in an exempt transaction coded "F" under Section 16b-3(e). This means shares were surrendered to the company to cover federal and state tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market. Following this transaction, the CFO beneficially owned 437,931 shares of Class A common stock directly.

An officer of Hinge Health, Inc. reported selling 15,000 shares of the company’s Class A common stock on 12/22/2025. The shares were sold in an open-market transaction at a weighted average price of $48.3967, with individual sale prices ranging from $47.785 to $48.74.

The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to allow insiders to trade on a scheduled basis. After this transaction, the reporting person beneficially owns 769,778 shares of Hinge Health’s Class A common stock. The total in Table I also reflects a correction to the reported ownership previously shown in Forms 4 filed on November 24, 2025 and December 1, 2025.

Hinge Health, Inc. Chief Financial Officer James Budge reported selling 10,491 shares of Class A common stock on 12/22/2025 in an open-market transaction. The shares were sold at a weighted average price of $48.4069 per share, with individual sale prices ranging from $47.81 to $48.74. The transaction was executed under a Rule 10b5-1 trading plan that he adopted on June 12, 2025. Following this sale, Budge beneficially owns 441,174 shares of Hinge Health Class A common stock, held directly.

Hinge Health, Inc. CEO, Co‑Founder, director and 10% owner reported insider transactions dated December 15, 2025. On that date, he converted 166,670 shares of Class B common stock into Class A common stock at an exercise price of $0, then disposed of the same 166,670 Class A shares in open‑market sales.

The first sale covered 161,250 Class A shares at a weighted average price of $48.5031, within a range of $47.98 to $48.96. The second sale covered 5,420 shares at a weighted average price of $49.2962, within a range of $49.00 to $49.58. All sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025.

After these transactions, he beneficially owned 14,543,427 shares of Class B common stock directly, plus 515,705 Class B shares and 35,470 Class A shares indirectly through his spouse.

Hinge Health, Inc. Chief Financial Officer James Budge reported a change in his holdings of the company’s Class A common stock. On 12/11/2025, he disposed of 20,000 shares at a reported price of $0 under transaction code G, leaving him with 451,665 shares of Class A common stock held directly after the transaction. This filing was made as a Form 4 by a single reporting person.

Hinge Health, Inc. reported an insider transaction by a person who is a director, CEO, co‑founder and 10% owner. On 12/10/2025, the insider converted 11,680 shares of Class B Common Stock into 11,680 shares of Class A Common Stock at a stated price of $0 per share. On 12/12/2025, those 11,680 Class A shares were transferred as a gift, leaving the insider with 0 directly held Class A shares.

Following these transactions, the insider reported 14,710,097 derivative securities related to Class B Common Stock held directly, and an additional 515,705 derivative securities and 35,470 Class A shares held indirectly through a spouse. Each share of Class B Common Stock is convertible into one share of Class A Common Stock under conditions described in the company’s charter.

Hinge Health, Inc. reported an insider-related share sale involving a major shareholder. A director and 10% owner filed to report sales made by affiliated Bessemer venture funds on December 5, 2025. Bessemer Venture Partners X L.P. sold 2,614 shares of Class A common stock and Bessemer Venture Partners X Institutional L.P. sold 2,453 shares at a weighted average price of $50.0166, in multiple trades between $50.00 and $50.12. The reporting person is a partner at Bessemer Venture Partners and describes only an indirect, passive economic interest in these fund-held shares, formally disclaiming beneficial ownership beyond any pecuniary interest.

Insight Venture Partners affiliates, identified as a director and 10% owner of Hinge Health, Inc. (HNGE), reported on Form 4 that on December 1, 2025 they converted multiple blocks of Class B Common Stock into Class A Common Stock and then sold those Class A shares.

The reporting persons converted and sold 826,216, 19,659, 677,508 and 131,057 shares of Class B/Class A stock, respectively, through affiliated Insight investment funds, with each corresponding Class A position shown as reduced to zero following the sales at a reported price of $47.76 per share.

Footnotes describe that each share of Class B Common Stock was convertible into one share of Class A Common Stock and outline Insight’s fund and holding-company structure, noting that various Insight entities and managers may be deemed to share voting and dispositive power over these Hinge Health shares while generally disclaiming beneficial ownership beyond their pecuniary interests.

Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.

After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.

Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.

The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.

Hinge Health, Inc. (HNGE) Chief Financial Officer James Budge reported open-market sales of Class A common stock under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. On November 25, 2025, he sold 15,730 shares at a weighted average price of $46.8822, 27,248 shares at a weighted average price of $47.7669, and 1,611 shares at a weighted average price of $48.2738, across specified price ranges. Following these transactions, Budge beneficially owned 479,878 shares of Hinge Health Class A common stock in direct ownership.

Hinge Health, Inc. (HNGE) President insider sale reported. A company officer filed a Form 4 showing open-market sales of a total of 15,000 shares of Class A common stock on 11/21/2025, executed in three transactions.

The shares were sold at weighted average prices of $44.3538, $45.7528, and $46.0885, within disclosed price ranges from $43.96 to $46.21. The transactions were made under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following these sales, the reporting person directly holds 789,902 shares of Class A common stock.

Hinge Health, Inc. (HNGE) reported an insider stock sale by one of its directors. On 11/21/2025, the reporting person sold 1,250 shares of Class A common stock in an open-market transaction coded as "S" at a weighted average price of $45.6848 per share, within a range of $45.68 to $45.71.

After this transaction, the director beneficially owns 27,750 shares of Hinge Health Class A common stock directly. No derivative securities transactions were reported in this filing.

Hinge Health, Inc. (HNGE) reported an insider stock sale by its Chief Financial Officer. On 11/20/2025, the CFO sold 781 shares of Class A common stock at a price of $44.78 per share in an open-market transaction coded as a sale. This transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to help insiders systematically sell shares over time. Following this sale, the CFO beneficially owns 524,467 shares of Hinge Health common stock in direct ownership.

Hinge Health, Inc. insider Bessemer entities reported major share moves. On November 18, 2025, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. converted a total of 4,108,707 shares of Class B Common Stock into 4,108,707 shares of Class A Common Stock under terms described in the company’s charter. On the same date, they sold 725,000 shares of Class A Common Stock at a price of $40.05 per share.

After these transactions, the Bessemer funds reported indirect beneficial ownership of 3,383,707 shares of Class A Common Stock, consisting of 1,745,316 shares held by BVP X and 1,638,391 shares held by BVP X Inst. The reporting entities are described as director-level affiliates and 10% owners of Hinge Health, reflecting significant ongoing ownership even after the sale.

Hinge Health, Inc. (HNGE) reported insider activity involving an individual who is both a director and 10% owner, with holdings tied to Bessemer Venture Partners funds. On November 18, 2025, Bessemer Venture Partners X L.P. converted 2,119,271 shares of Class B Common Stock into 2,119,271 shares of Class A Common Stock, and Bessemer Venture Partners X Institutional L.P. converted 1,989,436 Class B shares into 1,989,436 Class A shares.

On the same date, BVP X sold 373,955 shares of Hinge Health Class A Common Stock and BVP X Institutional sold 351,045 Class A shares. The reporting person, a partner at Bessemer Venture Partners, notes only an indirect, passive economic interest in these Bessemer funds and expressly disclaims beneficial ownership beyond any pecuniary interest.

Hinge Health, Inc. (HNGE) reported that one of its directors sold Class A common stock in two transactions. On 11/18/2025, the director sold 2,187 shares at an average price of $40.4556, leaving 32,813 shares beneficially owned. On 11/19/2025, the director sold an additional 3,813 shares at a weighted average price of $43.603, with a remaining holding of 29,000 shares, all held directly.

The company notes that the weighted average price on 11/19/2025 reflects individual sale prices between $43.51 and $43.73, and undertakes to provide detailed breakdowns of the shares sold at each price upon request.

Hinge Health, Inc. (HNGE) reported an insider equity transaction by its President on a Form 4. On 11/18/2025, the officer had 15,977 shares of Class A common stock withheld and cancelled at a price of $40.84 per share to cover federal and state tax obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). After this tax-withholding event, the officer beneficially owned 804,904 shares of Class A common stock, which include 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.

Hinge Health, Inc. (HNGE) reported an insider equity transaction by its Chief Financial Officer on 11/18/2025. The filing shows that 34,903 shares of Class A common stock were disposed of at $40.84 per share in a transaction classified as exempt under Section 16b-3(e). These shares were withheld and cancelled to cover federal and state tax obligations arising from the vesting of restricted stock units, rather than being sold in the open market.

After this tax-withholding event, the CFO beneficially owns 525,248 shares of Class A common stock. This total includes 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.